SGMO (STOCKS)
Sangamo Therapeutics, Inc. Common Stock
$0.398000
+0.019200 (+5.07%)
Prev close: $0.378800
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Alexander D. Macrae
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $139.89M
- Employees
- 183
- P/E (TTM)
- -0.87
- P/B (TTM)
- 19.54
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $32.88M |
| Benefits Costs and Expenses | $142.23M |
| Costs And Expenses | $142.23M |
| Operating Expenses | $141.90M |
| Research and Development | $104.91M |
| Other Operating Expenses | $36.99M |
| Operating Income/Loss | -$109.03M |
| Income/Loss From Continuing Operations After Tax | -$108.91M |
| Income/Loss From Continuing Operations Before Tax | -$109.35M |
| Income Tax Expense/Benefit | -$442.00K |
| Income Tax Expense/Benefit, Deferred | -$18.00K |
| Net Income/Loss | -$108.91M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$108.91M |
| Net Income/Loss Available To Common Stockholders, Basic | -$108.91M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.45 |
| Diluted Earnings Per Share | -$0.45 |
| Basic Average Shares | 263,653,000 |
| Diluted Average Shares | 263,653,000 |
| Assets | $88.64M |
| Current Assets | $44.08M |
| Noncurrent Assets | $44.57M |
| Fixed Assets | $14.79M |
| Other Non-current Assets | $29.77M |
| Liabilities | $82.40M |
| Current Liabilities | $50.13M |
| Accounts Payable | $15.56M |
| Other Current Liabilities | $34.57M |
| Noncurrent Liabilities | $32.28M |
| Equity | $6.24M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $6.24M |
| Liabilities And Equity | $88.64M |
| Net Cash Flow From Operating Activities | -$76.16M |
| Net Cash Flow From Operating Activities, Continuing | -$76.16M |
| Net Cash Flow From Investing Activities | $1.24M |
| Net Cash Flow From Investing Activities, Continuing | $1.24M |
| Net Cash Flow From Financing Activities | $62.94M |
| Net Cash Flow From Financing Activities, Continuing | $62.94M |
| Exchange Gains/Losses | $1.80M |
| Net Cash Flow | -$10.17M |
| Net Cash Flow, Continuing | -$11.98M |
| Comprehensive Income/Loss | -$106.13M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$106.13M |
| Other Comprehensive Income/Loss | -$106.13M |